Deutsch, Germany
Deutsch, Germany

MorphoSys AG is a German biotechnology company. It is involved in the development and research of antibodies. TecDAX has listed MorphoSys since 2004. Wikipedia.


Time filter

Source Type

Patent
MorphoSys | Date: 2017-04-05

The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.


Patent
MorphoSys | Date: 2015-06-09

The present disclosure relates to fusion proteins that are highly useful for the generation of virus-like particles for the display of membrane spanning proteins. Related embodiments, methods and uses are disclosed.


Patent
MorphoSys | Date: 2017-04-26

The present disclosure relates to fusion proteins that are highly useful for the generation of virus-like particles for the display of membrane spanning proteins. Related embodiments, methods and uses are disclosed.


Patent
MorphoSys | Date: 2015-04-30

The invention relates to novel libraries of linear and cyclic peptides, and methods of generating and screening such libraries for biological, pharmaceutical and other uses.


Patent
MorphoSys | Date: 2017-03-10

The present invention provides synthetic rodent antibody libraries, such as mouse or rat antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries and variants of such antibodies.


Patent
MorphoSys | Date: 2017-03-08

The invention relates to novel libraries of linear and cyclic peptides, and methods of generating and screening such libraries for biological, pharmaceutical and other uses.


Patent
MorphoSys | Date: 2016-03-31

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.


The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.


Patent
MorphoSys | Date: 2015-09-09

The invention provides a human or humanized anti-CD38 antibody or functional fragment thereof, wherein said antibody or functional fragment thereof is able to mediate killing of a CD38+ target cell by ADCC with an at least five-fold better efficacy than chimeric OKT10 under the same or substantially the same conditions when a human PBMC cell is employed as an effector cell, wherein said CD38+ target cell is selected from the group consisting of LP-1 and RPMI-8226, and wherein the ratio of effector cells to target cells is between about 30:1 and about 50:1. The invention further provides a human or humanized anti-CD38 antibody or functional fragment thereof, wherein said antibody or functional fragment thereof is able to mediate killing of a CD38-transfected CHO cell by CDC with an at least two-fold better efficacy than chimeric OKT10 under the same or substantially the same conditions. The invention further provides a human or humanized anti-CD38 antibody, wherein said antibody binds to an epitope of CD38 comprising one or more amino acid residues of amino acid residues 1 to 215 of CD38. Nucleic acids encoding the antibodies of the invention as well as therapeutic uses of the antibodies are also provided.


The invention provides a human antibody that is specific for CD38. The antibody of the invention has the ability to bind to CD38 of minipig origin and induce, by cross-linking, specific killing of cells, in particular tumor cells, expressing CD38. The invention further provides uses of this antibody for treating various disorders and conditions associated with undesired presence of CD38+ cells, including hematological and inflammatory diseases. The invention also provides diagnostic compositions and methods based on detecting the presence of CD38 in a tissue or a cell of minipig origin contacted with the antibody of the invention.

Loading MorphoSys collaborators
Loading MorphoSys collaborators